Put companies on watchlist
Cantourage Group SE
ISIN: DE000A3DSV01
WKN: A3DSV0
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cantourage Group SE · ISIN: DE000A3DSV01 · EQS - Company News (47 News)
Country: Germany · Primary market: Germany · EQS NID: 1700097
10 August 2023 09:00AM

New partner focuses on particularly resource-saving aeroponic cultivation technology


EQS-News: Cantourage Group SE / Key word(s): Market Launch
Cantourage Group SE welcomes SUMO Cannabis: New partner focuses on particularly resource-saving aeroponic cultivation technology

10.08.2023 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

Cantourage Group SE welcomes SUMO Cannabis: New partner focuses on particularly resource-saving aeroponic cultivation technology

Berlin, August 10, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01), a leading European company for the production and distribution of medicinal cannabis, has announced that SUMO Cannabis, another major producer, has been acquired as a partner to supply to the European market for medicinal cannabis. Patients in Germany, who can already obtain medical cannabis as a medicine through pharmacies, will thus benefit from an even better supply of high-quality cannabis flowers in the future.

SUMO Cannabis maintains its cultivation operation in Trois-Rivières, in the heart of the province of Québec, Canada. With currently 25 employees, the company that has been licensed under the Cannabis Act and Cannabis Regulations (Health Canada) since February 2022, operates a state-of-the-art aeroponic cultivation facility that allows for particularly resource-efficient cultivation. In addition to very low energy and water consumption, this cultivation practice gives growers full control over important parameters such as nutrient content and pH levels.

With the approval of the cultivar Apex OG, Cantourage is expanding its product range in the craft cannabis segment and thus strengthening the security of supply for patients in Germany.

“We are excited to offer our flowers to the European market for the first time, a significant milestone for our young company. The partnership will allow us to share our passion for premium cannabis with the discerning patients in Germany, offering them even more choice of high-quality medical cannabis strains,” said Éric Morel, CEO of SUMO Cannabis.

“We are delighted to have gained another cultivation partner in SUMO Cannabis, who shares our passion for cannabis products. More and more international growers are actively seeking to work with us, which shows that our model works and is seen as exemplary in the industry,” added Philip Schetter, CEO of Cantourage.

About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.

More information: www.cantourage.com

About SUMO Cannabis
SUMO Cannabis is a licensed cannabis producer based in Trois-Rivières, Québec, Canada. Using advanced indoor aeroponic growing technology, the company cultivates high-quality craft cannabis that meets the most demanding requirements of the industry. Their goal is to maximize the potential of cannabis as a valuable and versatile natural product while maintaining the highest quality standards. As a licensed facility, SUMO Cannabis works closely with the federal cannabis distribution authorities in Canada to supply to the domestic market. By working with Cantourage, the company is now supplying its premium flower to the European market for the first time.

For further information: https://sumocannabis.com/

This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

Press contact Cantourage:
Tonka Communications
+49 (0)176 7471 7519
cantourage@tonka-pr.com



10.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Berlin, Frankfurt (Scale), Munich, Tradegate Exchange
EQS News ID: 1700097

 
End of News EQS News Service

1700097  10.08.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1700097&application_name=news&site_id=boersengefluester
Visual performance / price development - Cantourage Group SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.